Harold Pierce, MD
Urology · Laramie, WYNPI 1639262595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Neotract Inc. at 40.1% of the total. Reporting peaked in 2019 at $676 and has fallen 90.2% since, to $66 in 2024.
Across 36 payments — averaging $45.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$657
- Coloplast$423
- Astellas Pharma US Inc$213
- Sumitomo Pharma America, Inc.$104
- Myovant Sciences Inc.$68
- Boston Scientific$39
- plus $132 from 7 others
What the payments were for
- Travel & lodging$68842%
- Food & beverage$74546%
- Education$20312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 9 | $657 |
| Coloplast | 4 | $423 |
| Astellas Pharma US Inc | 3 | $213 |
| Sumitomo Pharma America, Inc. | 5 | $104 |
| Myovant Sciences Inc. | 4 | $68 |
| Boston Scientific | 2 | $39 |
| Olympus America Inc. | 2 | $32 |
| Laborie Medical Technologies Corp. | 1 | $26 |
| SRS Medical Systems, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 2 | $17 |
| 180 Medical, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 84 | $76,065 |
| Tamsulosin Hcl | 525 | $11,212 |
| GemtesaVibegron | 11 | $8,448 |
| Finasteride | 342 | $6,733 |
| Potassium Citrate ErPotassium Citrate | 37 | $5,192 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 18 | $4,376 |
| Oxybutynin Chloride ErOxybutynin Chloride | 64 | $1,849 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 45 | $1,601 |
| Dutasteride | 23 | $1,171 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 67 | $1,168 |
| Solifenacin Succinate | 16 | $562 |
| Bicalutamide | 18 | $543 |
| Doxazosin Mesylate | 21 | $377 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 104 | $329 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $213 | $76,06584 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $104 | $8,44811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other urology in Laramie
- William FlockLaramie$13
- John BryantCheyenne$8K
- Henry GottschCasper$4K
- Brandon TrojanCasper$4K
- Cody ChristensenRock Springs$4K
- Ted MorganJackson$3K
- Stephen HolstSheridan$3K
- Attila BarabasGillette$3K
- John JonesCasper$2K
- Wallace CurryRock Springs$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.